MiMedx to Present at The 10th Annual Craig-Hallum Institutional Investor Conference
KENNESAW, Ga., May 22, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 10th Annual Craig-Hallum Institution Investor Conference in Minneapolis. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO and Michael J. Senken, Chief Financial Officer, are scheduled to present on May 29, 2013 at 10:05 a.m. Central Time at the Minneapolis Marriott City Center.
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 150,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.
More by this Source
MiMedx Receives Additional Medicare Reimbursement Coverage for EpiFix®
Dec 12, 2013, 12:27 ET
MiMedx Group Announces Proposed Public Offering of Common Stock
Dec 09, 2013, 07:00 ET
MiMedx Schedules Conference Call To Discuss Impact Of CMS Policy And Ongoing FDA Discussions
Dec 05, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.